{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:59:30Z","timestamp":1791352770483,"version":"4.3.1"},"reference-count":66,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.3892\/ijo.2015.3055","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T11:20:07Z","timestamp":1434626407000},"page":"437-445","source":"Crossref","is-referenced-by-count":21,"title":["Molecular aspects of breast cancer resistance to drugs (Review)"],"prefix":"10.3892","volume":"47","author":[{"given":"GLORIA M.","family":"CALAF","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDREA B.","family":"ZEPEDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RODRIGO L.","family":"CASTILLO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAROLINA A.","family":"FIGUEROA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CONSUELO","family":"ARIAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EL\u00cdAS","family":"FIGUEROA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JORGE G.","family":"FAR\u00cdAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,6,18]]},"reference":[{"key":"key20180107190922_b1-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000341394","article-title":"A mechanistic study of the effect of doxorubicin\/adriamycin on the estrogen response in a breast cancer model","volume":"83","author":"Pritchard","year":"2012","journal-title":"Oncology"},{"key":"key20180107190922_b2-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr3460","article-title":"Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis","volume":"15","author":"Borges","year":"2013","journal-title":"Breast Cancer Res"},{"key":"key20180107190922_b3-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/path.2808","article-title":"The molecular pathology of breast cancer progression","volume":"223","author":"Bombonati","year":"2011","journal-title":"J Pathol"},{"key":"key20180107190922_b4-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.artmed.2009.07.008","article-title":"Mixture classification model based on clinical markers for breast cancer prognosis","volume":"48","author":"Zeng","year":"2010","journal-title":"Artif Intell Med"},{"key":"key20180107190922_b5-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00428-014-1593-7","article-title":"Molecular classification of breast cancer","volume":"465","author":"Vuong","year":"2014","journal-title":"Virchows Arch"},{"key":"key20180107190922_b6-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ijc.27767","article-title":"Distinct tumor protein p53 mutants in breast cancer subgroups","volume":"132","author":"Dumay","year":"2013","journal-title":"Int J Cancer"},{"key":"key20180107190922_b7-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.12659\/MSM.894010","article-title":"Association between four MMP-9 polymorphisms and breast cancer risk: A meta-analysis","volume":"21","author":"Zhang","year":"2015","journal-title":"Med Sci Monit"},{"key":"key20180107190922_b8-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.breast.2012.08.005","article-title":"Association between common risk factors and molecular subtypes in breast cancer patients","volume":"22","author":"Turkoz","year":"2013","journal-title":"Breast"},{"key":"key20180107190922_b9-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"key20180107190922_b10-ijo-47-02-0437","first-page":"1362","article-title":"Epidemiology of breast cancer","volume":"63","author":"Arveux","year":"2013","journal-title":"Rev Prat"},{"key":"key20180107190922_b11-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.annepidem.2014.02.011","article-title":"Multiple metabolic risk factors and mammographic breast density","volume":"24","author":"Tehranifar","year":"2014","journal-title":"Ann Epidemiol"},{"key":"key20180107190922_b12-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1245\/s10434-009-0479-4","article-title":"Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients","volume":"16","author":"Vadaparampil","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"key20180107190922_b13-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"e98251","DOI":"10.1371\/journal.pone.0098251","article-title":"A polymorphism rs12325489C>T in the lincRNA-ENST00000515084 exon was found to modulate breast cancer risk via GWAS-based association analyses","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"key20180107190922_b14-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180107190922_b15-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ajpath.2013.04.033","article-title":"Epigenetic modifications in breast cancer and their role in personalized medicine","volume":"183","author":"Stefansson","year":"2013","journal-title":"Am J Pathol"},{"key":"key20180107190922_b16-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","article-title":"Prognostic and predictive factors in early-stage breast cancer","volume":"9","author":"Cianfrocca","year":"2004","journal-title":"Oncologist"},{"key":"key20180107190922_b17-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1093\/annonc\/mdt183","article-title":"A simple and reproducible prognostic index in luminal ER-positive breast cancers","volume":"24","author":"Castellano","year":"2013","journal-title":"Ann Oncol"},{"key":"key20180107190922_b18-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cncr.11083","article-title":"Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor","volume":"97","author":"Chang","year":"2003","journal-title":"Cancer"},{"key":"key20180107190922_b19-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"284036","DOI":"10.1155\/2013\/284036","article-title":"Sex hormone receptor repertoire in breast cancer","volume":"2013","author":"Higa","year":"2013","journal-title":"Int J Breast Cancer"},{"key":"key20180107190922_b20-ijo-47-02-0437","first-page":"4332","article-title":"HER-2\/neu amplification predicts poor survival in node-positive breast cancer","volume":"50","author":"Borg","year":"1990","journal-title":"Cancer Res"},{"key":"key20180107190922_b21-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"e91771","DOI":"10.1371\/journal.pone.0091771","article-title":"CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance","volume":"9","author":"Gao","year":"2014","journal-title":"PLoS One"},{"key":"key20180107190922_b22-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.3390\/ijms12074504","article-title":"Putative biomarkers and targets of estrogen receptor negative human breast cancer","volume":"12","author":"Sahab","year":"2011","journal-title":"Int J Mol Sci"},{"key":"key20180107190922_b23-ijo-47-02-0437","first-page":"42","article-title":"A novel targeted therapy in breast cancer: Cyclin dependent kinase inhibitors","volume":"19","author":"Akin","year":"2014","journal-title":"J BUON"},{"key":"key20180107190922_b24-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nchembio.695","article-title":"A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer","volume":"7","author":"Muellner","year":"2011","journal-title":"Nat Chem Biol"},{"key":"key20180107190922_b25-ijo-47-02-0437","unstructured":"American Cancer Society2013Breast Cancer Facts and Figures 2013\u20132014AtlantaAmerican Cancer Society2013http:\/\/www.cancer.org\/acs\/groups\/content\/@research\/documents\/document\/acspc-042725.pdf"},{"key":"key20180107190922_b26-ijo-47-02-0437","unstructured":"World Health Organization (WHO)Guidelines for management of breast cancer2006http:\/\/applications.emro.who.int\/dsaf\/dsa697.pdf"},{"key":"key20180107190922_b27-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1200\/JCO.2007.14.1168","article-title":"Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer","volume":"26","author":"Dawood","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107190922_b28-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-014-2857-2","article-title":"A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells","volume":"144","author":"Borges","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107190922_b29-ijo-47-02-0437","first-page":"62","article-title":"Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer","volume":"1795","author":"Zilli","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"key20180107190922_b30-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10863-013-9519-7","article-title":"Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin","volume":"45","author":"Tavares-Valente","year":"2013","journal-title":"J Bioenerg Biomembr"},{"key":"key20180107190922_b31-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu Rev Med"},{"key":"key20180107190922_b32-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.suc.2012.12.002","article-title":"Adjuvant systemic therapies in breast cancer","volume":"93","author":"Hernandez-Aya","year":"2013","journal-title":"Surg Clin North Am"},{"key":"key20180107190922_b33-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/theoncologist.2008-0816","article-title":"FDA drug approval summary: Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2","volume":"13","author":"Ryan","year":"2008","journal-title":"Oncologist"},{"key":"key20180107190922_b34-ijo-47-02-0437","first-page":"34","article-title":"Mechanisms of anticancer drugs. Scott-Brown\u2019s Otorhinolaryngology","volume":"7","author":"Payne","year":"2008","journal-title":"Head Neck Surg"},{"key":"key20180107190922_b35-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/emmm.201303411","article-title":"Sox2 promotes tamoxifen resistance in breast cancer cells","volume":"6","author":"Piva","year":"2014","journal-title":"EMBO Mol Med"},{"key":"key20180107190922_b36-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12094-012-0929-5","article-title":"MicroRNAs and drug resistance of breast cancer: Basic evidence and clinical applications","volume":"15","author":"Tian","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"key20180107190922_b37-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s12032-011-0117-4","article-title":"Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer","volume":"29","author":"Chen","year":"2012","journal-title":"Med Oncol"},{"key":"key20180107190922_b38-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1007\/s11033-011-1347-4","article-title":"EGFR-mediated G1\/S transition contributes to the multidrug resistance in breast cancer cells","volume":"39","author":"Chen","year":"2012","journal-title":"Mol Biol Rep"},{"key":"key20180107190922_b39-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"key20180107190922_b40-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ctrv.2008.01.007","article-title":"Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer","volume":"34","author":"Coley","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"key20180107190922_b41-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrc3107","article-title":"MicroRNA regulation by RNA-binding proteins and its implications for cancer","volume":"11","author":"van Kouwenhove","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 3","key":"key20180107190922_b42-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0960-9776(11)70293-4","article-title":"Biological mechanisms and clinical implications of endocrine resistance in breast cancer","volume":"20","author":"Giuliano","year":"2011","journal-title":"Breast"},{"key":"key20180107190922_b43-ijo-47-02-0437","first-page":"491","article-title":"Potential of antibody-drug conjugates and novel therapeutics in breast cancer management","volume":"7","author":"Lianos","year":"2014","journal-title":"Onco Targets Ther"},{"key":"key20180107190922_b44-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.prp.2014.01.008","article-title":"Prognostic factors in patients with metastatic breast cancer at the time of diagnosis","volume":"210","author":"Ren","year":"2014","journal-title":"Pathol Res Pract"},{"key":"key20180107190922_b45-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/2278-330X.130445","article-title":"Late effects of cancer treatment in breast cancer survivors","volume":"3","author":"Agrawal","year":"2014","journal-title":"South Asian J Cancer"},{"issue":"Suppl","key":"key20180107190922_b46-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"S2270","DOI":"10.1002\/cncr.27462","article-title":"Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors","volume":"118","author":"Schmitz","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"key20180107190922_b47-ijo-47-02-0437","first-page":"541550","article-title":"Adjuvant endocrine therapy for breast cancer","volume":"26","author":"Rao","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"key20180107190922_b48-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tem.2004.05.011","article-title":"Breast cancer, stem\/ progenitor cells and the estrogen receptor","volume":"15","author":"Dontu","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"key20180107190922_b49-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107190922_b50-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem Cell"},{"key":"key20180107190922_b51-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"R10","DOI":"10.1186\/bcr1855","article-title":"Brca1 breast tumors contain distinct CD44+\/CD24\u2212 and CD133+ cells with cancer stem cell characteristics","volume":"10","author":"Wright","year":"2008","journal-title":"Breast Cancer Res"},{"key":"key20180107190922_b52-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1524-4741.2010.00910.x","article-title":"Circulating tumor cells and biomarkers: Implications for personalized targeted treatments for metastatic breast cancer","volume":"16","author":"Reuben","year":"2010","journal-title":"Breast J"},{"key":"key20180107190922_b53-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymeth.2014.03.005","article-title":"Breast cancer patient stratification using a molecular regularized consensus clustering method","volume":"67","author":"Wang","year":"2014","journal-title":"Methods"},{"key":"key20180107190922_b54-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1758834014521111","article-title":"Anti-inflammatory\/antioxidant use in long-term maintenance cancer therapy: A new therapeutic approach to disease progression and recurrence","volume":"6","author":"Crawford","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"key20180107190922_b55-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.14694\/EdBook_AM.2014.34.e478","article-title":"Nutritional supplements and cancer: potential benefits and proven harms","volume":"34","author":"Harvie","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20180107190922_b56-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ejca.2014.02.013","article-title":"Vitamin C and survival among women with breast cancer: A meta-analysis","volume":"50","author":"Harris","year":"2014","journal-title":"Eur J Cancer"},{"key":"key20180107190922_b57-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.currproblcancer.2007.04.001","article-title":"Role of curcumin in cancer therapy","volume":"31","author":"Shishodia","year":"2007","journal-title":"Curr Probl Cancer"},{"key":"key20180107190922_b58-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1208\/s12248-009-9128-x","article-title":"Curcumin and cancer cells: How many ways can curry kill tumor cells selectively?","volume":"11","author":"Ravindran","year":"2009","journal-title":"AAPS J"},{"key":"key20180107190922_b59-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2174\/09298673113206660135","article-title":"Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment","volume":"21","author":"Hasima","year":"2014","journal-title":"Curr Med Chem"},{"key":"key20180107190922_b60-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1568009053202081","article-title":"Induction of apoptosis by curcumin and its implications for cancer therapy","volume":"5","author":"Karunagaran","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"key":"key20180107190922_b61-ijo-47-02-0437","first-page":"436","article-title":"Effect of curcumin on irradiated and estrogen-transformed human breast cell lines","volume":"40","author":"Calaf","year":"2012","journal-title":"Int J Oncol"},{"key":"key20180107190922_b62-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7243\/2052-6199-1-6","article-title":"Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers","volume":"1","author":"Cridge","year":"2013","journal-title":"Oncol Discov"},{"key":"key20180107190922_b63-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5604\/17322693.1102294","article-title":"Curcumin in chemoprevention of breast cancer","volume":"68","author":"Terlikowska","year":"2014","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"key20180107190922_b64-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1083\/jcb.201102147","article-title":"The extracellular matrix: A dynamic niche in cancer progression","volume":"196","author":"Lu","year":"2012","journal-title":"J Cell Biol"},{"key":"key20180107190922_b65-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/1471-2407-14-331","article-title":"Epistemology of the origin of cancer: A new paradigm","volume":"14","author":"Br\u00fccher","year":"2014","journal-title":"BMC Cancer"},{"key":"key20180107190922_b66-ijo-47-02-0437","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1091\/mbc.E14-03-0825","article-title":"The role of TGF-\u03b2 receptor III localization in polarity and breast cancer progression","volume":"25","author":"Meyer","year":"2014","journal-title":"Mol Biol Cell"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2015.3055\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T19:13:46Z","timestamp":1515352426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2015.3055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,18]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,6,18]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.3892\/ijo.2015.3055"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2015.3055","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,18]]}}}